Jun 2026 (Q2 FY26) — Aug 4, 2026
IDEXX Q2 FY26 — Strong Diagnostics Growth and Raised Full-Year Outlook
Read the full callIDEXX (IDXX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
IDEXX earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,217 | +9.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 35.0 | +1.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 338 | +15.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
29 of 29 judged targets kept · 23 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Q2 FY26 CAG Diagnostics recurring revenue growth | 8.5% to 10.5% | Mar 2026 | Strong CAG results were supported by CAG Diagnostics recurring revenue growth of 10.3% organically, net of a 50 basis point negative impact related to equivalent days | Achieved |
| Full-year CAG Diagnostics recurring revenue growth | 8% to 10% | Dec 2025 | organic CAG Diagnostics recurring revenue growth of 9.5% to 10.7% | Revised Up |
| Full-year capital spending | $180 million | Dec 2025 | including full year capital spending consistent at approximately $180 million | On Track |
23 of IDEXX LABORATORIES INC /DE's 52 targets are still open. See which are on track and which have gone quiet. The 3 above are the free sample; 49 more targets are in the full ledger.
Claimed
- Revenue increased 10% as reported and 9% organically in Q2 FY26.
- CAG Diagnostics recurring revenues grew over 10% organically, with double-digit gains in both U.S. and international regions.
- Comparable operating margin gained 110 basis points, supported by gross margin expansion.
- Comparable EPS grew 15% to $4.27 in Q2 FY26.
- Free cash flow conversion on a trailing 12-month basis was 110%.
Qualified
- U.S. same-store clinical visits declined an estimated 1.3% in Q2 FY26.
- Wellness visits declined below 3% in the U.S. during Q2 FY26.
- CAG Diagnostic instrument revenues declined 20% organically in Q2 FY26 due to lapping the broad commercial availability of inVue Dx in the prior year period.
Price
$555.8 −0.81% · −$4.56
Performance −12.5% 1Y
1Y: $635.4 on 17 Oct 2025 → $555.8. High $766.68 (25 Nov 2025), low $504.7 (11 Sept 2026).
- Previous close
- $560.36
- 52-week range
- $504.7 – $766.68
- One year
- −13.62%
Overview
- Symbol
- IDXX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
29 of 29 judged targets kept · 23 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Q2 FY26 CAG Diagnostics recurring revenue growth | 8.5% to 10.5% | Mar 2026 | Strong CAG results were supported by CAG Diagnostics recurring revenue growth of 10.3% organically, net of a 50 basis point negative impact related to equivalent days | Achieved |
| Full-year CAG Diagnostics recurring revenue growth | 8% to 10% | Dec 2025 | organic CAG Diagnostics recurring revenue growth of 9.5% to 10.7% | Revised Up |
| Full-year capital spending | $180 million | Dec 2025 | including full year capital spending consistent at approximately $180 million | On Track |
Claimed
- Revenue increased 10% as reported and 9% organically in Q2 FY26.
- CAG Diagnostics recurring revenues grew over 10% organically, with double-digit gains in both U.S. and international regions.
- Comparable operating margin gained 110 basis points, supported by gross margin expansion.
- Comparable EPS grew 15% to $4.27 in Q2 FY26.
- Free cash flow conversion on a trailing 12-month basis was 110%.
Qualified
- U.S. same-store clinical visits declined an estimated 1.3% in Q2 FY26.
- Wellness visits declined below 3% in the U.S. during Q2 FY26.
- CAG Diagnostic instrument revenues declined 20% organically in Q2 FY26 due to lapping the broad commercial availability of inVue Dx in the prior year period.
The full ledger
Open IDEXX LABORATORIES INC /DE’s full ledger
A free account opens 5 company ledgers a month. All 52 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
IDEXX Laboratories Q1 FY26 — Strong Diagnostics Growth Despite Clinical Visit Headwinds
Read the full callDec 2025 (Q4 FY25) — Feb 2, 2026
IDEXX Laboratories Q4 FY25 — Strong Growth Driven by Innovation and Premium Instrument Placements
Read the full callEvery analysed call
IDEXX earnings calls (IDXX)
Financials
What the filings say
Net profit, year on year: +15% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 976 | 954 | 998 | 1,109 | 1,105 | 1,091 | 1,141 | 1,217 |
| Operating profit | 304 | 262 | 317 | 373 | 355 | 316 | 363 | 426 |
| Operating margin | 31.1% | 27.4% | 31.7% | 33.6% | 32.1% | 28.9% | 31.8% | 35.0% |
| Interest | 8 | 7 | 8 | 11 | 11 | 9 | 8 | 10 |
| Profit before tax | 299 | 256 | 310 | 362 | 345 | 307 | 355 | 417 |
| Tax rate | 22.1% | 15.7% | 21.7% | 18.9% | 20.4% | 19.1% | 21.7% | 18.9% |
| Net profit | 233 | 216 | 243 | 294 | 275 | 248 | 278 | 338 |
| EPS ($ per share) | 2.83 | — | 2.98 | 3.66 | 3.43 | — | 3.50 | 4.29 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 1,168 | 1,596 | 2,176 | 2,920 | 3,600 | 4,445 | 5,332 | 6,392 |
| Total liabilities | 1,547 | 1,655 | 1,662 | 1,747 | 2,138 | 1,775 | 1,698 | 1,745 |
| Fixed assets | 437 | 534 | 555 | 588 | 649 | 702 | 713 | 747 |
| Total assets | 1,537 | 1,832 | 2,295 | 2,437 | 2,747 | 3,260 | 3,293 | 3,351 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 400 | 459 | 648 | 756 | 543 | 907 | 929 | 1,182 |
| Cash from investing | 139 | -206 | -109 | -293 | -195 | -125 | -207 | -136 |
| Cash from financing | -598 | -286 | -248 | -697 | -371 | -442 | -878 | -1,165 |
| Net cash flow | -64 | -33 | 294 | -239 | -32 | 341 | -166 | -108 |
| Capital expenditure | -116 | -155 | -107 | -120 | -149 | -134 | -121 | -125 |
| Free cash flow | 284 | 304 | 541 | 636 | 394 | 773 | 808 | 1,057 |
IDXX revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Companion Animal Group | 91% | 91% | 92% | 92% | 92% | 92% | 92% | 92% | +9.4% |
| Water | 5% | 5% | 5% | 5% | 5% | 5% | 4% | 5% | +14.8% |
| Livestock and Poultry Diagnostics | 3% | 4% | 3% | 3% | 3% | 3% | 3% | 3% | +10.8% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
IDXX operating KPIs by quarter
| KPI | Mar 2025 Q1 FY25 | Jun 2025 Q2 FY25 | Sep 2025 Q3 FY25 | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|---|---|---|
| Premium instrument placements | 4,163During Q1, we placed 4,163 CAG premium instruments, a decline of 13% against high prior-year levels.Source: earnings call transcript | 6,070Total premium placements reached 6,070 units, an increase of 23% year-over-year.Source: earnings call transcript | 5,665Total premium placements reached 5,665 units, an increase of 37% year-over-year.Source: earnings call transcript | 6,567In the fourth quarter, we placed 6,567 premium instruments, up 42% from the prior year.Source: earnings call transcript | 4,650CAG premium instrument placements reached 4,650 units during the first quarter, an increase of 12% year-over-year and the quality of placements remains superb reflected in over 1,000 global new and competitive catalyst placements, including nearly 320 in North America.Source: earnings call transcript | 5,265CAG premium instrument placements reached 5,265 units during the second quarter resulting in an expected year-over-year decline as we lap the broad commercial availability of inVue Dx in the prior year.Source: earnings call transcript | +13.2% |
| Employees | — | 11KAs I conclude our prepared remarks, I want to express my deep appreciation for our 11,000 IDEXX employees worldwide.Source: earnings call transcript | 11KAs we conclude, I want to extend my deep gratitude to our 11,000 IDEXX employees worldwide.Source: earnings call transcript | 11KI want to close by thanking our 11,000 employees around the world.Source: earnings call transcript | ~11KOur approximately 11,000 IDEXX employees around the world are purpose-driven and our talent fuels the company's growth.Source: earnings call transcript | — | — |
| IDEXX InVue Dx instrument placements | — | — | 1,753Globally, we placed 1,753 IDEXX InVue Dx instruments as we continue to meet customer demand for this highly innovative analyzer.Source: earnings call transcript | 1,900+We achieved record premium instrument placements in Q4, with strong gains across our major platforms, including over 1,900 IDEXX inVue Dx placements, supporting a 69% organic year-over-year expansion of our CAG Diagnostic instrument revenues.Source: earnings call transcript | 1,100Strong premium instrument placements in the quarter resulted in 28% organic growth of CAG instrument revenues and included 1,100 IDEXX inVue Dx analyzers.Source: earnings call transcript | 1,602Globally, we placed 1,602 IDEXX inVue Dx instruments in Q2 and over 1,000 new and competitive catalyst instruments globally with nearly 300 in the US IDEXX global reference lab revenues increased over 10% organically in Q2, led by volume gains.Source: earnings call transcript | +45.6% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2026 · share of revenue
- US 64% ↓ 2 pt
- EMEA 22% ↑ 1 pt
- Asia Pacific 8%
- CA 4%
- Latin American and Caribbean 2%
As IDXX cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
119 filings between Oct 30, 2025 and Sep 4, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$37.66M
36 sales by 6 insiders
Compensation
not trading decisions- 4
- Award — granted as compensation
- 67
- Option exercise — converted options into shares
- 12
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| MAZELSKY JONATHAN JAY | — | $15.34M | Feb 26, 2026 |
| Hunt Nimrata | — | $9.53M | Mar 3, 2026 |
| FENNELL GEORGE | — | $7.34M | Feb 10, 2026 |
| Erickson Michael G | — | $3.37M | Feb 17, 2026 |
| Kingsley Lawrence D | — | $1.17M | Sep 4, 2026 |
| Vandebroek Sophie V. | — | $920.3K | Feb 17, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 4, 2026 | Kingsley Lawrence D Director | Sale | 2,203 | $1.17M |
| Sep 4, 2026 | Kingsley Lawrence D Director | Option exercise | 2,203 | $251.5K |
| Aug 20, 2026 | Emerson Andrew EVP, CFO and Treasurer | Tax withheld | 86 | $0 |
| Aug 20, 2026 | Emerson Andrew EVP, CFO and Treasurer | Option exercise | 265 | $47.2K |
| Jul 30, 2026 | HOOLEY JOSEPH L Director | Award | 49 | $27.4K |
| Jun 1, 2026 | FENNELL GEORGE Executive Vice President | Option exercise | 639 | $0 |
| Jun 1, 2026 | FENNELL GEORGE Executive Vice President | Tax withheld | 284 | $161.0K |
| May 7, 2026 | SZOSTAK M ANNE Director | Option exercise | 257 | $0 |
| May 7, 2026 | JUNIUS DANIEL M Director | Option exercise | 257 | $0 |
| May 7, 2026 | Kingsley Lawrence D Director | Option exercise | 82 | $0 |
| May 7, 2026 | HOOLEY JOSEPH L Director | Option exercise | 158 | $0 |
| May 7, 2026 | Peacock Karen Director | Option exercise | 101 | $0 |
| May 7, 2026 | Vandebroek Sophie V. Director | Option exercise | 257 | $0 |
| May 7, 2026 | Kingsley Lawrence D Director | Option exercise | 257 | $0 |
| Apr 30, 2026 | HOOLEY JOSEPH L Director | Award | 43 | $24.1K |
| Mar 3, 2026 | Underberg Sharon E. EVP, GC & Corporate Secretary | Option exercise | 197 | $99.6K |
| Mar 3, 2026 | Hunt Nimrata Executive Vice President | Sale | 1,758 | $1.12M |
| Feb 27, 2026 | MAZELSKY JONATHAN JAY President and CEO | Option exercise | 197 | $99.6K |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 1,000 | $662.2K |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 2,589 | $1.72M |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 2,860 | $1.88M |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 2,859 | $1.89M |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Option exercise | 23,326 | $3.30M |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 3,660 | $2.41M |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 1,111 | $727.3K |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 1,200 | $793.3K |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 1,171 | $765.5K |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 1,343 | $882.1K |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 1,669 | $1.09M |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 1,488 | $975.9K |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 1,281 | $833.5K |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY President and CEO | Sale | 1,095 | $713.4K |
| Feb 26, 2026 | Hunt Nimrata Executive Vice President | Sale | 2,693 | $1.78M |
| Feb 19, 2026 | Erickson Michael G Executive Vice President | Option exercise | 183 | $99.6K |
| Feb 19, 2026 | Erickson Michael G Executive Vice President | Option exercise | 483 | $100.0K |
| Feb 19, 2026 | Erickson Michael G Executive Vice President | Option exercise | 817 | $145.6K |
| Feb 19, 2026 | Erickson Michael G Executive Vice President | Option exercise | 719 | $101.8K |
| Feb 19, 2026 | Erickson Michael G Executive Vice President | Option exercise | 197 | $99.6K |
| Feb 17, 2026 | Vandebroek Sophie V. Director | Option exercise | 945 | $315.5K |
| Feb 17, 2026 | Erickson Michael G Executive Vice President | Sale | 40 | $25.2K |
| Feb 17, 2026 | Erickson Michael G Executive Vice President | Sale | 689 | $433.4K |
| Feb 17, 2026 | Erickson Michael G Executive Vice President | Sale | 2,694 | $1.69M |
| Feb 17, 2026 | Erickson Michael G Executive Vice President | Sale | 1,288 | $806.6K |
| Feb 17, 2026 | Erickson Michael G Executive Vice President | Sale | 204 | $127.5K |
| Feb 17, 2026 | Erickson Michael G Executive Vice President | Sale | 456 | $284.4K |
| Feb 17, 2026 | Erickson Michael G Executive Vice President | Option exercise | 4,180 | $745.1K |
| Feb 17, 2026 | Erickson Michael G Executive Vice President | Option exercise | 1,191 | $168.6K |
| Feb 17, 2026 | Vandebroek Sophie V. Director | Sale | 519 | $326.2K |
| Feb 17, 2026 | Vandebroek Sophie V. Director | Sale | 945 | $594.1K |
| Feb 14, 2026 | Emerson Andrew EVP, CFO and Treasurer | Option exercise | 42 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for IDEXX LABORATORIES INC /DE
Free account. Everything above stays public.
Write why you follow IDEXX LABORATORIES INC /DE and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading